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Thepurposeofthispaperistoassesstheeﬃcacyofgreencoﬀeeextract(GCE)asaweightlosssupplement,usingdatafromhuman
clinical trials. Electronic and nonelectronic searches were conducted to identify relevant articles, with no restrictions in time or
language. Two independent reviewers extracted the data and assessed the methodological quality of included studies. Five eligible
trials were identiﬁed, and three of these were included. All studies were associated with a high risk of bias. The meta-analytic result
reveals a signiﬁcant diﬀerence in body weight in GCE compared with placebo (mean diﬀerence: −2.47kg; 95%CI: −4.23, −0.72).
The magnitude of the eﬀect is moderate, and there is signiﬁcant heterogeneity amongst the studies. It is concluded that the results
from these trials are promising, but the studies are all of poor methodological quality. More rigorous trials are needed to assess the
usefulness of GCE as a weight loss tool.
1.Introduction
Overweight and obesity have become a serious health
concern [1]. Diﬀerent weight management strategies are
presently utilised, and a variety of weight loss supplements
sold as “slimming aids” are readily available. However,
the eﬃcacy of some of these food supplements remains
uncertain. One such supplement is the green coﬀee extract
(GCE).
GCE is present in green or raw coﬀee [2]. It is also
present in roasted coﬀee, but much of the GCE is destroyed
during the roasting process. Some GCE constituents, such
as chlorogenic acid (CGA) can also be found in a variety of
fruits and vegetables [3]. The daily intake of CGA in persons
drinking coﬀe ev a r i e sf r o m0 . 5t o1 g[ 4]. The traditional
method of extraction of GCE from green coﬀee bean, Coﬀea
canephora robusta, involves the use of alcohol as a solvent
[5]. Extracted GCE is marketed as a weight loss supplement
under a variety of brand names as a weight loss supplement
such as “Coﬀee Slender”, and “Svetol”.
Evidence is accumulating from animal studies regarding
the use of GCE as a weight loss supplement [6, 7]. In
human subjects, coﬀee intake has been reported to be
inversely associated with weight gain [8]. Consumption of
coﬀee has also been shown to produce changes in several
glycaemic markers in older adults [9]. Similarly, other
research has indicated that the consumption of caﬀeinated
coﬀee can lead to some reductions in long-term weight
gain, an eﬀect which is likely to be due to the known
thermogenic eﬀects of caﬀeine intake as well as eﬀects of
GCE and other pharmacologically active substances present
in coﬀee [10]. GCE has also been postulated to modify
hormone secretion and glucose tolerance in humans [11].
This eﬀect is accomplished by facilitating the absorption of
glucose from the distal, rather than the proximal part of the
gastrointestinal tract.
The objective of this paper is to analyse the results of
human clinical trials assessing the eﬃcacy of GCE as a
weight-reducing agent.2 Gastroenterology Research and Practice
2. Methods
Electronic searches of the literature were conducted for
the following databases: MEDLINE, EMBASE, CINAHL,
AMED, and The Cochrane Library. Each database was
searched from inception up until April, 2010. Search terms
used included coﬀee, green coﬀee, green coﬀee extract,
roasted coﬀee, decaﬀeinated coﬀee, chlorogenic acid, caf-
feoylquinic acid, antiobesity agent, appetite suppressant,
abdominal fat, BMI, body mass index, body fat, body
weight, overweight, over weight, corpulen∗,o b e s ∗,w e i g h t
loss, weight decrease, weight watch, weight cycle, weight
control, weight gain, weight maintenance, weight reduc-
tion, weight change, dietary supplement, food supplement,
nutraceutical,nutri∗supplement,over-the-counterOROTC,
nonprescription drugs, randomised controlled trial, clinical
trial, and placebo. We also searched other internet databases
for relevant conference proceedings, as well as our own ﬁles.
Hand searches of the bibliography of retrieved full texts were
also conducted.
Only randomised, double-blind, and placebo-controlled
studies were included in this paper. To be considered for
inclusion, studies had to test the eﬃcacy of GCE for weight
reduction in obese or overweight humans. Included studies
also had to report body weight and/or body mass index
(BMI) as an outcome. No age, time, or language restrictions
wereimposedforinclusionofstudies.Studieswhichinvolved
the use of GCE as part of a combination treatment or not
involving obese or overweight subjects were excluded from
this paper.
Two independent reviewers assessed the eligibility of
studies to be included in the paper. Data were extracted
systematically by two independent reviewers according to
the patient characteristics, interventions, and results. The
methodological quality of all included studies was assessed
by the use of a quality assessment checklist adapted from
the consolidated standard of reporting trials (CONSORT)
guidelines [12, 13]. Disagreements were resolved through
discussion with the third author.
Data are presented as means with standard deviations.
Mean changes in body weight were used as common
endpoints to assess the diﬀerences between GCE and placebo
groups. Using the standard meta-analysis software [14],
we calculated mean diﬀerences (MD) and 95% conﬁdence
intervals (CI). The I2 statistic was used to assess for statistical
heterogeneity amongst studies.
3. Results
Our searches produced 2160 “hits”. 328 articles were
excluded because they were duplicate citations, while 767
articles were excluded because of wrong titles and abstracts.
Another 598 articles were excluded because they did not
investigateafoodsupplements,and454articlesexcludeddue
to no report on clinical outcome. A further 13 articles were
excluded due to unsuitable study design. Thus, 5 potentially
relevant articles were identiﬁed (Figure 1). One trial was
excluded because it involved only normal weight individuals,
and did not measure weight as an outcome [15]. Another
trial was excluded because it was not randomised [16]. In
eﬀect, 3 randomised clinical trials (RCTs) including a total
of 142 participants met our inclusion criteria, and were
includedinthissystematicpaper[5,17,18].Theirkeydetails
are summarized in Tables 1 and 2.
Af o r e s tp l o t( r a n d o m - e ﬀect model) for the three trials
is shown in ﬁgure 2. The meta-analysis reveals a statistically
signiﬁcant diﬀerence in body weight between GCE and
placebo (MD: −2.47kg; 95% CI: −4.23,−0.72). The I2
statistic of 97% suggests that there is considerable hetero-
geneity amongst the studies. A further plot of two trials
which involved CGA-enriched GCE revealed a statistically
nonsigniﬁcant diﬀerence in body weight between GCE and
placebo (MD: −1.92kg; 95% CI: −5.40, 1.56). Heterogeneity
was also considerable in this analysis (I2 statistic of 99%).
One of the studies reported a statistically signiﬁcant decrease
in the percentage of body fat in the GCE group compared
with baseline, but no signiﬁcant diﬀerence in the placebo
group [5]. There was no mention of intergroup diﬀerences
regarding the percentage of body fat. None of the trials
reported any adverse events associated with the use of
GCE.
4. Discussion
The main purpose of this systematic paper was to assess
the eﬃcacy of GCE as a weight loss supplement. The
overall meta-analysis revealed a signiﬁcant diﬀerence in
change in body weight between GCE and placebo. The
magnitude of this signiﬁcance is moderate, and the clinical
relevance is therefore not certain. There is also considerable
heterogeneity amongst the three trials.
In animals, GCE has been reported to inﬂuence post-
prandrial glucose concentration and blood lipid concen-
tration [5]. This is thought to be via reduction in the
absorption of glucose in the intestine; a mechanism achieved
by promoting dispersal of the Na+ electrochemical gra-
dient. This dispersal leads to an inﬂux of glucose into
the enterocytes [19]. GCE is also thought to inhibit the
enzymatic activity of hepatic glucose-6-phosphatase, which
is involved in the homeostasis of glucose [20]. Reports
from animal studies have suggested that GCE mediates its
antiobesity eﬀect possibly by suppressing the accumulation
of hepatic triglycerides [6]. Some authors have also posited
that the antiobesity eﬀect of GCE may be mediated via
alterationofplasmaadipokinelevelandbodyfatdistribution
and downregulating fatty acid and cholesterol biosynthesis,
whereas upregulating fatty acid oxidation and peroxisome
proliferator-activated receptor alpha (PPARα) expression in
the liver [7].
Diets rich in polyphenols may help to prevent various
kinds of diseases associated with oxidative stress, including
coronary heart disease and some forms of cancer [21,
22]. GCE has been reported to have antioxidant activity,
demonstrated by its ability to scavenge free radicals in vitro,
and to increase the antioxidant capacity of plasma in vivo
[16, 23]. There is also evidence that certain dietary phenols,
including GCE, may modify intestinal glucose uptake in aGastroenterology Research and Practice 3
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2 articles excluded for the following reasons:
- Only normal weight individuals: 1
3 randomised clinical
trials included
5 full texts retrieved for more
detailed evaluation of the articles
2160 references
retrieved
2155 articles excluded based on duplicate citations;
wrong title/abstract; did not investigate a food
supplement for weight loss; did not report clinical
outcome; or the study design was unsuitable
- Nonrandomised study: 1
Figure 1: Flow chart for inclusion of randomised clinical trials.
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Thom 2007
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Test for overall eﬀect: Z = 2.76 (P = .006)
75 67
Study or subgroup Mean Mean
GCE
SD SD Total Total Weight
Mean diﬀerence
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Mean diﬀerence
IV, random, 95% CI
−2.47 [−4.23, −0.72]
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Heterogeneity: τ2 = 2.3; χ2 = 61.66, df = 2( P< .00001); I2 = 97%
Figure 2: Forest plot showing the eﬀect of GCE on body weight.
number of ways [8, 24]. This activity might provide a basis
for explaining its eﬀects on body weight. The purported
slimmingeﬀectofGCEwouldhaveaprotectiveeﬀectagainst
diabetes mellitus, via changes in gastrointestinal hormone
secretion[10].Afewquestions,however,arisefromtheRCTs
which involve the use of GCE as a weight loss aid.
All the RCTs involving the use of GCE which have been
conductedsofarhaveverysmallsamplesizes,withthelargest
number of participants being 62 in one trial [17]. These
small sample sizes increase the possibility of spurious or false
positive results. Two of the RCTs were unclear about drop-
outs of participants from the trial; neither did they report
on intention-to-treat analysis [17, 18]. All of the trials so far
identiﬁed have been of very short duration. This makes it
diﬃcult to assess the eﬃcacy and safety of GCE as a weight
reduction agent on the medium to long-term. Although
none of the RCTs identiﬁed reported any adverse events,
this does not indicate that GCE intake is “risk-free”. Two
participants in a study report dropped out due to adverse
eventsassociatedwiththeintakeofGCE[16].Theseincluded
headache and urinary tract infection. Thus, the safety of this
weight loss aid is not established.
The eﬀective dosage of GCE for use as a weight loss
supplement is also not established. The dosages of GCE
reported in most of the human trials identiﬁed were
estimated, as the GCE was a component of coﬀee. While 2
of the RCTs identiﬁed enriched their GCE with CGA [5, 17],
the third trial did not report that the GCE used was fortiﬁed
with CGA [18]. This warrants further investigation.
The RCTs identiﬁed from our searches were not also
clear on blinding issues. None of the RCTs reported on
how randomisation was carried out, and none provided
information regarding blinding of outcome assessors. This
casts doubt on the internal validity of these trials. Future
trials involving the use of GCE as a weight loss supplement
should be conducted in line with the CONSORT guidelines.
Thiswillensurethevalidityandapplicabilityofstudyresults.
Two authors in one study were aﬃliated to a company which
m a r k e t sS v e t o l[ 18] but did not specify whether or not they
had any conﬂicts of interest.6 Gastroenterology Research and Practice
This systematic review has several limitations. Though
our search strategy involved both electronic and nonelec-
tronic studies, we may not have identiﬁed all the available
trials involving the use of GCE as a weight loss supplement.
Furthermore, the methodological quality of the studies
identiﬁed from our searches is poor, and all are of short
duration. These factors prevent us from drawing ﬁrm
conclusions about the eﬀects of GCE on body weight.
5. Conclusion
The evidence from RCTs seems to indicate that the intake of
GCE can promote weight loss. However, several caveats exist.
Thesizeoftheeﬀectissmall,andtheclinicalrelevanceofthis
eﬀect is uncertain. More rigorous trials with longer duration
areneededtoassesstheeﬃcacyandsafetyofGCEasaweight
loss supplement.
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